Neurometabolic Disorders Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Neurometabolic Disorders Market to 2027 - Global Analysis and Forecasts By Disease Type (Fabry Disease, Gaucher's Disease, Pompe Disease, Maroteaux-Lamy Syndrome, Others); Route of Administration (Parenteral, Oral) and Geography

Report Code: TIPRE00004205 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Neurometabolic disorders or the neurogenetic are abonormalities that affects the brain functions. The disorders are seen in all age groups. The disorders are caused due to the abnormal functions of the gene that can lead to various chronic diseases and rare diseases. The disorder does not have specific treatment or cures however, precise diagnosis is important to understand the underlying cause so that future treatments can be offered.

MARKET DYNAMICS
The neurometabolic disorders market is anticipated due to the key driving factors such as rising healthcare expenditures, rising awareness about the diseases, rise in the technological advancement and others. The market is likely to gain growth opportunities owing to the developments in the technologies for genomics that are likely to offer treatments for the rare diseases.

MARKET SCOPE
The "Global Neurometabolic Disorders Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of neurometabolic disorders market with detailed market segmentation by disease type, route of administration and geography. The global neurometabolic disorders market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading neurometabolic disorders market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global neurometabolic disorders market is segmented on the basis of disease type and route of administration. Based on the disease type the market is segmented as fabry disease, gaucher's disease, pompe disease, maroteaux-lamy syndrome and others. Based on the route of administration the market is classified as parenteral and oral.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global neurometabolic disorders market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The neurometabolic disorders market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting neurometabolic disorders market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Neurometabolic disorders market in these regions.

MARKET PLAYERS
The reports cover key developments in the neurometabolic disorders market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from neurometabolic disorders market are anticipated to lucrative growth opportunities in the future with the rising demand for neurometabolic disorders market in the global market. Below mentioned is the list of few companies engaged in the neurometabolic disorders market.

The report also includes the profiles of key neurometabolic disorders market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Amicus Therapeutics, Inc.
  • Zywie LLC (ExSAR Corporation)
  • Greenovation Biotech GmbH
  • ISU ABXIS
  • Protalix Biotherapeutics
  • BioMarin Pharmaceutical Inc
  • Genzyme Corporation (Sanofi)
  • Shire (Takeda Pharmaceutical Company Limited)
  • Celerion
  • Orchard Therapeutics plc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neurometabolic Disorders Market - By Disease Type
1.3.2 Neurometabolic Disorders Market - By Route of Administration
1.3.3 Neurometabolic Disorders Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. NEUROMETABOLIC DISORDERS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NEUROMETABOLIC DISORDERS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NEUROMETABOLIC DISORDERS MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROMETABOLIC DISORDERS - GLOBAL MARKET OVERVIEW
6.2. NEUROMETABOLIC DISORDERS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NEUROMETABOLIC DISORDERS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. FABRY DISEASE
7.3.1. Overview
7.3.2. Fabry Disease Market Forecast and Analysis
7.4. GAUCHER'S DISEASE
7.4.1. Overview
7.4.2. Gaucher's Disease Market Forecast and Analysis
7.5. POMPE DISEASE
7.5.1. Overview
7.5.2. Pompe Disease Market Forecast and Analysis
7.6. MAROTEAUX-LAMY SYNDROME
7.6.1. Overview
7.6.2. Maroteaux-Lamy Syndrome Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. NEUROMETABOLIC DISORDERS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. PARENTERAL
8.3.1. Overview
8.3.2. Parenteral Market Forecast and Analysis
8.4. ORAL
8.4.1. Overview
8.4.2. Oral Market Forecast and Analysis
9. NEUROMETABOLIC DISORDERS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Neurometabolic Disorders Market Overview
9.1.2 North America Neurometabolic Disorders Market Forecasts and Analysis
9.1.3 North America Neurometabolic Disorders Market Forecasts and Analysis - By Disease Type
9.1.4 North America Neurometabolic Disorders Market Forecasts and Analysis - By Route of Administration
9.1.5 North America Neurometabolic Disorders Market Forecasts and Analysis - By Countries
9.1.5.1 United States Neurometabolic Disorders Market
9.1.5.1.1 United States Neurometabolic Disorders Market by Disease Type
9.1.5.1.2 United States Neurometabolic Disorders Market by Route of Administration
9.1.5.2 Canada Neurometabolic Disorders Market
9.1.5.2.1 Canada Neurometabolic Disorders Market by Disease Type
9.1.5.2.2 Canada Neurometabolic Disorders Market by Route of Administration
9.1.5.3 Mexico Neurometabolic Disorders Market
9.1.5.3.1 Mexico Neurometabolic Disorders Market by Disease Type
9.1.5.3.2 Mexico Neurometabolic Disorders Market by Route of Administration
9.2. EUROPE
9.2.1 Europe Neurometabolic Disorders Market Overview
9.2.2 Europe Neurometabolic Disorders Market Forecasts and Analysis
9.2.3 Europe Neurometabolic Disorders Market Forecasts and Analysis - By Disease Type
9.2.4 Europe Neurometabolic Disorders Market Forecasts and Analysis - By Route of Administration
9.2.5 Europe Neurometabolic Disorders Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Neurometabolic Disorders Market
9.2.5.1.1 Germany Neurometabolic Disorders Market by Disease Type
9.2.5.1.2 Germany Neurometabolic Disorders Market by Route of Administration
9.2.5.2 France Neurometabolic Disorders Market
9.2.5.2.1 France Neurometabolic Disorders Market by Disease Type
9.2.5.2.2 France Neurometabolic Disorders Market by Route of Administration
9.2.5.3 Italy Neurometabolic Disorders Market
9.2.5.3.1 Italy Neurometabolic Disorders Market by Disease Type
9.2.5.3.2 Italy Neurometabolic Disorders Market by Route of Administration
9.2.5.4 Spain Neurometabolic Disorders Market
9.2.5.4.1 Spain Neurometabolic Disorders Market by Disease Type
9.2.5.4.2 Spain Neurometabolic Disorders Market by Route of Administration
9.2.5.5 United Kingdom Neurometabolic Disorders Market
9.2.5.5.1 United Kingdom Neurometabolic Disorders Market by Disease Type
9.2.5.5.2 United Kingdom Neurometabolic Disorders Market by Route of Administration
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Neurometabolic Disorders Market Overview
9.3.2 Asia-Pacific Neurometabolic Disorders Market Forecasts and Analysis
9.3.3 Asia-Pacific Neurometabolic Disorders Market Forecasts and Analysis - By Disease Type
9.3.4 Asia-Pacific Neurometabolic Disorders Market Forecasts and Analysis - By Route of Administration
9.3.5 Asia-Pacific Neurometabolic Disorders Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Neurometabolic Disorders Market
9.3.5.1.1 Australia Neurometabolic Disorders Market by Disease Type
9.3.5.1.2 Australia Neurometabolic Disorders Market by Route of Administration
9.3.5.2 China Neurometabolic Disorders Market
9.3.5.2.1 China Neurometabolic Disorders Market by Disease Type
9.3.5.2.2 China Neurometabolic Disorders Market by Route of Administration
9.3.5.3 India Neurometabolic Disorders Market
9.3.5.3.1 India Neurometabolic Disorders Market by Disease Type
9.3.5.3.2 India Neurometabolic Disorders Market by Route of Administration
9.3.5.4 Japan Neurometabolic Disorders Market
9.3.5.4.1 Japan Neurometabolic Disorders Market by Disease Type
9.3.5.4.2 Japan Neurometabolic Disorders Market by Route of Administration
9.3.5.5 South Korea Neurometabolic Disorders Market
9.3.5.5.1 South Korea Neurometabolic Disorders Market by Disease Type
9.3.5.5.2 South Korea Neurometabolic Disorders Market by Route of Administration
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Neurometabolic Disorders Market Overview
9.4.2 Middle East and Africa Neurometabolic Disorders Market Forecasts and Analysis
9.4.3 Middle East and Africa Neurometabolic Disorders Market Forecasts and Analysis - By Disease Type
9.4.4 Middle East and Africa Neurometabolic Disorders Market Forecasts and Analysis - By Route of Administration
9.4.5 Middle East and Africa Neurometabolic Disorders Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Neurometabolic Disorders Market
9.4.5.1.1 South Africa Neurometabolic Disorders Market by Disease Type
9.4.5.1.2 South Africa Neurometabolic Disorders Market by Route of Administration
9.4.5.2 Saudi Arabia Neurometabolic Disorders Market
9.4.5.2.1 Saudi Arabia Neurometabolic Disorders Market by Disease Type
9.4.5.2.2 Saudi Arabia Neurometabolic Disorders Market by Route of Administration
9.4.5.3 U.A.E Neurometabolic Disorders Market
9.4.5.3.1 U.A.E Neurometabolic Disorders Market by Disease Type
9.4.5.3.2 U.A.E Neurometabolic Disorders Market by Route of Administration
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Neurometabolic Disorders Market Overview
9.5.2 South and Central America Neurometabolic Disorders Market Forecasts and Analysis
9.5.3 South and Central America Neurometabolic Disorders Market Forecasts and Analysis - By Disease Type
9.5.4 South and Central America Neurometabolic Disorders Market Forecasts and Analysis - By Route of Administration
9.5.5 South and Central America Neurometabolic Disorders Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Neurometabolic Disorders Market
9.5.5.1.1 Brazil Neurometabolic Disorders Market by Disease Type
9.5.5.1.2 Brazil Neurometabolic Disorders Market by Route of Administration
9.5.5.2 Argentina Neurometabolic Disorders Market
9.5.5.2.1 Argentina Neurometabolic Disorders Market by Disease Type
9.5.5.2.2 Argentina Neurometabolic Disorders Market by Route of Administration
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. NEUROMETABOLIC DISORDERS MARKET, KEY COMPANY PROFILES
11.1. AMICUS THERAPEUTICS, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ZYWIE LLC (EXSAR CORPORATION)
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. GREENOVATION BIOTECH GMBH
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ISU ABXIS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. PROTALIX BIOTHERAPEUTICS
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. BIOMARIN PHARMACEUTICAL INC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GENZYME CORPORATION (SANOFI)
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SHIRE (TAKEDA PHARMACEUTICAL COMPANY LIMITED)
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. CELERION
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. ORCHARD THERAPEUTICS PLC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Amicus Therapeutics, Inc.
2. Zywie LLC (ExSAR Corporation)
3. Greenovation Biotech GmbH
4. ISU ABXIS
5. Protalix Biotherapeutics
6. BioMarin Pharmaceutical Inc
7. Genzyme Corporation (Sanofi)
8. Shire (Takeda Pharmaceutical Company Limited)
9. Celerion
10. Orchard Therapeutics plc.